The contract is currently for 665,000 doses, with the possibility to buy up to 40 million doses over four years.
HERA, which has been in talks with CSL Seqirus for months, approached the company last year to ask it to update its zoonotic flu vaccine to the dominant circulating avian flu strain. But to do so, CSL Seqirus asked for a minimum guarantee of sale, to make the transaction profitable — something HERA could guarantee through the joint procurement.
CSL Seqirus’s adapted zoonotic influenza vaccine was given the backing of the European Medicines Agency (EMA) in…
